Apoptosis inhibitor TRIAP1 is a novel effector of drug resistance

Adams,Caroline; Cazzanelli,Giulia; Rasul,Sabeena; Hitchinson,Ben; Hu,Yunhui; Coombes,R.   Charles; Raguz,Selina; Yagüe,Ernesto

doi:10.3892/or.2015.3988

Apoptosis inhibitor TRIAP1 is a novel effector of drug resistance

Authors:
- Caroline Adams
- Giulia Cazzanelli
- Sabeena Rasul
- Ben Hitchinson
- Yunhui Hu
- R. Charles Coombes
- Selina Raguz
- Ernesto Yagüe
View Affiliations

Affiliations: Cancer Research Centre, Division of Cancer, Imperial College London, Hammersmith Hospital Campus, London W12 0NN, UK, Institute of Clinical Sciences, Imperial College London, Hammersmith Hospital Campus, London W12 0NN, UK
Published online on: May 19, 2015 https://doi.org/10.3892/or.2015.3988
Pages: 415-422

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

TP53-regulated inhibitor of apoptosis 1 (TRIAP1) is a novel apoptosis inhibitor that binds HSP70 in the cytoplasm and blocks the formation of the apoptosome and caspase-9 activation. TRIAP1 has been shown to be upregulated in many types of cancers; however, its role remains elusive. We determined the TRIAP1 mRNA levels in a panel of human tissues and found its expression to be ubiquitous. Normal breast, as well as non-tumorigenic breast cells, exhibited lower TRIAP1 mRNA levels than breast cancer cells or their drug-resistant derivatives. TRIAP1 is a small, evolutionarily conserved protein that is 76 amino acids long. We found that yeast cells, in which the TRIAP1 homologue was knocked out, had increased sensitivity to doxorubicin. Equally, RNA interference in breast cancer drug-resistant cells demonstrated that downregulation of TRIAP1 impaired cell growth in the presence of doxorubicin. As expected, caspase-9 activation was diminished after overexpression of TRIAP1 in drug-resistant cells. Importantly, stable transfections of a TRIAP1 expression plasmid in CAL51 cells led to a marked increase in the number of doxorubicin‑resistant clones, that was abolished when cells expressed hairpins targeting TRIAP1. In addition, we showed that TRIAP1 expression was also triggered by estrogen deprivation in MCF-7 cells. Although both polyclonal and monoclonal antibodies generated for the present study failed to robustly detect TRIAP1, we demonstrated that TRIAP1 represents a novel marker for drug resistance in breast cancer cells and it may be used in the stratification of breast cancer patients once a suitable antibody has been developed. Equally, these studies open potential drug development strategies for blocking TRIAP1 activity and avoiding drug resistance.

View Figures

View References

1	Mashima T and Tsuruo T: Defects of the apoptotic pathway as therapeutic target against cancer. Drug Resist Updat. 8:339–343. 2005. View Article : Google Scholar : PubMed/NCBI
2	Indran IR, Tufo G, Pervaiz S and Brenner C: Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochim Biophys Acta. 1807:735–745. 2011. View Article : Google Scholar : PubMed/NCBI
3	Elmore S: Apoptosis: a review of programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
4	Cotter TG: Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer. 9:501–507. 2009. View Article : Google Scholar : PubMed/NCBI
5	Yu Q: Restoring p53-mediated apoptosis in cancer cells: new opportunities for cancer therapy. Drug Resist Updat. 9:19–25. 2006. View Article : Google Scholar : PubMed/NCBI
6	Kastan MB: Wild-type p53: tumors can’t stand it. Cell. 128:837–840. 2007. View Article : Google Scholar : PubMed/NCBI
7	de Graaf AO, de Witte T and Jansen JH: Inhibitor of apoptosis proteins: new therapeutic targets in hematological cancer? Leukemia. 18:1751–1759. 2004. View Article : Google Scholar : PubMed/NCBI
8	Park WR and Nakamura Y: p53CSV, a novel p53-inducible gene involved in the p53-dependent cell-survival pathway. Cancer Res. 65:1197–1206. 2005. View Article : Google Scholar : PubMed/NCBI
9	Tamura Y, Iijima M and Sesaki H: Mdm35p imports Ups proteins into the mitochondrial intermembrane space by functional complex formation. EMBO J. 29:2875–2887. 2010. View Article : Google Scholar : PubMed/NCBI
10	Niu P, Liu L, Gong Z, Tan H, Wang F, Yuan J, Feng Y, Wei Q, Tanguay RM and Wu T: Overexpressed heat shock protein 70 protects cells against DNA damage caused by ultraviolet C in a dose-dependent manner. Cell Stress Chaperones. 11:162–169. 2006. View Article : Google Scholar : PubMed/NCBI
11	Salvesen GS and Duckett CS: IAP proteins: blocking the road to death’s door. Nat Rev Mol Cell Biol. 3:401–410. 2002. View Article : Google Scholar : PubMed/NCBI
12	Felix RS, Colleoni GW, Caballero OL, Yamamoto M, Almeida MS, Andrade VC, Chauffaille MdeL, Silva WA Jr, Begnami MD, Soares FA, et al: SAGE analysis highlights the importance of p53csv, ddx5, mapkapk2 and ranbp2 to multiple myeloma tumorigenesis. Cancer Lett. 278:41–48. 2009. View Article : Google Scholar : PubMed/NCBI
13	Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 10:515–527. 2006. View Article : Google Scholar : PubMed/NCBI
14	Ali S and Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2:101–112. 2002. View Article : Google Scholar
15	Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, et al: Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res. 15:R922013. View Article : Google Scholar : PubMed/NCBI
16	Raguz S, Adams C, Masrour N, Rasul S, Papoutsoglou P, Hu Y, Cazzanelli G, zhou Y, Patel N, Coombes C, et al: Loss of O’-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells. Biochem Pharmacol. 85:186–196. 2013. View Article : Google Scholar
17	Chen J, Gomes AR, Monteiro LJ, Wong SY, Wu LH, Ng TT, Karadedou CT, Millour J, Ip YC, Cheung YN, et al: Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer. PLoS One. 5:e122932010. View Article : Google Scholar : PubMed/NCBI
18	Tolhurst RS, Thomas RS, Kyle FJ, Patel H, Periyasamy M, Photiou A, Thiruchelvam PT, Lai CF, Al-Sabbagh M, Fisher RA, et al: Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth. Breast Cancer Res Treat. 128:357–368. 2011. View Article : Google Scholar
19	Rasul S, Balasubramanian R, Filipović A, Slade MJ, Yagüe E and Coombes RC: Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells. Br J Cancer. 100:1879–1888. 2009. View Article : Google Scholar : PubMed/NCBI
20	Yagüe E, Arance A, Kubitza L, O’Hare M, Jat P, Ogilvie CM, Hart IR, Higgins CF and Raguz S: Ability to acquire drug resistance arises early during the tumorigenesis process. Cancer Res. 67:1130–1137. 2007. View Article : Google Scholar : PubMed/NCBI
21	Filipović A, Gronau JH, Green AR, Wang J, Vallath S, Shao D, Rasul S, Ellis IO, Yagüe E, Sturge J, et al: Biological and clinical implications of nicastrin expression in invasive breast cancer. Breast Cancer Res Treat. 125:43–53. 2011. View Article : Google Scholar
22	Vichai V and Kirtikara K: Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 1:1112–1116. 2006. View Article : Google Scholar
23	Yague E, Armesilla AL, Harrison G, Elliott J, Sardini A, Higgins CF and Raguz S: P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J Biol Chem. 278:10344–10352. 2003. View Article : Google Scholar : PubMed/NCBI
24	Raguz S, De Bella MT, Slade MJ, Higgins CF, Coombes RC and Yagüe E: Expression of RPIP9 (Rap2 interacting protein 9) is activated in breast carcinoma and correlates with a poor prognosis. Int J Cancer. 117:934–941. 2005. View Article : Google Scholar : PubMed/NCBI
25	Almeida B, Silva A, Mesquita A, Sampaio-Marques B, Rodrigues F and Ludovico P: Drug-induced apoptosis in yeast. Biochim Biophys Acta. 1783:1436–1448. 2008. View Article : Google Scholar : PubMed/NCBI
26	Sun JM, Spencer VA, Li L, Yu Chen H, Yu J and Davie JR: Estrogen regulation of trefoil factor 1 expression by estrogen receptor alpha and Sp proteins. Exp Cell Res. 302:96–107. 2005. View Article : Google Scholar
27	Nachmias B, Ashhab Y and Ben-Yehuda D: The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol. 14:231–243. 2004. View Article : Google Scholar : PubMed/NCBI
28	Wang S, Bai L, Lu J, Liu L, Yang CY and Sun H: Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeutics. J Mammary Gland Biol Neoplasia. 17:217–228. 2012. View Article : Google Scholar : PubMed/NCBI
29	Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
30	Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M, van de Rijn M, Rosen GD, Perou CM, Whyte RI, et al: Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA. 98:13784–13789. 2001. View Article : Google Scholar : PubMed/NCBI
31	Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, et al: Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 10:3291–3300. 2004. View Article : Google Scholar : PubMed/NCBI
32	Skrzypczak M, Goryca K, Rubel T, Paziewska A, Mikula M, Jarosz D, Pachlewski J, Oledzki J and Ostrowski J: Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS One. 5:e130912010. View Article : Google Scholar : PubMed/NCBI
33	Molinari AM, Bontempo P, Schiavone EM, Tortora V, Verdicchio MA, Napolitano M, Nola E, Moncharmont B, Medici N, Nigro V, et al: Estradiol induces functional inactivation of p53 by intracellular redistribution. Cancer Res. 60:2594–2597. 2000.PubMed/NCBI
34	Fernández-Cuesta L, Anaganti S, Hainaut P and Olivier M: Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines. Breast Cancer Res Treat. 125:35–42. 2011. View Article : Google Scholar
35	Somaï S, Chaouat M, Jacob D, Perrot JY, Rostène W, Forgez P and Gompel A: Antiestrogens are pro-apoptotic in normal human breast epithelial cells. Int J Cancer. 105:607–612. 2003. View Article : Google Scholar : PubMed/NCBI
36	Zhang GJ, Kimijima I, Onda M, Kanno M, Sato H, Watanabe T, Tsuchiya A, Abe R and Takenoshita S: Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels. Clin Cancer Res. 5:2971–2977. 1999.PubMed/NCBI
37	Potting C, Tatsuta T, König T, Haag M, Wai T, Aaltonen MJ and Langer T: TRIAP1/PRELI complexes prevent apoptosis by mediating intramitochondrial transport of phosphatidic acid. Cell Metab. 18:287–295. 2013. View Article : Google Scholar : PubMed/NCBI
38	Cain K: Chemical-induced apoptosis: formation of the Apaf-1 apoptosome. Drug Metab Rev. 35:337–363. 2003. View Article : Google Scholar